E3 ubiquitin ligase-mediated regulation of bone formation and tumorigenesis

被引:0
作者
N Sévère
F-X Dieudonné
P J Marie
机构
[1] Laboratory of Osteoblast Biology and Pathology,
[2] INSERM U606,undefined
[3] University Paris Diderot,undefined
[4] Sorbonne Paris Cité,undefined
来源
Cell Death & Disease | 2013年 / 4卷
关键词
ubiquitin ligases; proteasome; receptor tyrosine kinases; bone tumors; Cbl proteins; ubiquitination;
D O I
暂无
中图分类号
学科分类号
摘要
The ubiquitination–proteasome and degradation system is an essential process that regulates protein homeostasis. This system is involved in the regulation of cell proliferation, differentiation and survival, and dysregulations in this system lead to pathologies including cancers. The ubiquitination system is an enzymatic cascade that mediates the marking of target proteins by an ubiquitin label and thereby directs their degradation through the proteasome pathway. The ubiquitination of proteins occurs through a three-step process involving ubiquitin activation by the E1 enzyme, allowing for the transfer to a ubiquitin-conjugated enzyme E2 and to the targeted protein via ubiquitin-protein ligases (E3), the most abundant group of enzymes involved in ubiquitination. Significant advances have been made in our understanding of the role of E3 ubiquitin ligases in the control of bone turnover and tumorigenesis. These ligases are implicated in the regulation of bone cells through the degradation of receptor tyrosine kinases, signaling molecules and transcription factors. Initial studies showed that the E3 ubiquitin ligase c-Cbl, a multi-domain scaffold protein, regulates bone resorption by interacting with several molecules in osteoclasts. Further studies showed that c-Cbl controls the ubiquitination of signaling molecules in osteoblasts and in turn regulates osteoblast proliferation, differentiation and survival. Recent data indicate that c-Cbl expression is decreased in primary bone tumors, resulting in excessive receptor tyrosine kinase signaling. Consistently, c-Cbl ectopic expression reduces bone tumorigenesis by promoting tyrosine kinase receptor degradation. Here, we review the mechanisms of action of E3 ubiquitin ligases in the regulation of normal and pathologic bone formation, and we discuss how targeting the interactions of c-Cbl with some substrates may be a potential therapeutic strategy to promote osteogenesis and to reduce tumorigenesis.
引用
收藏
页码:e463 / e463
相关论文
共 580 条
[11]  
Robertson M(1998)Transcriptional control of osteoblast differentiation Biochem Soc Trans 26 14-105
[12]  
Husnjak K(2008)Transcription factors controlling osteoblastogenesis Arch Biochem Biophys 473 98-137
[13]  
Dikic I(2000)Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis Endocr Rev 21 115-2685
[14]  
de Bie P(2003)Runx2/Cbfa1: a multifunctional regulator of bone formation Curr Pharm Des 9 2677-273
[15]  
Ciechanover A(2011)Bone development: overview of bone cells and signaling Curr Osteoporos Rep 9 264-3768
[16]  
Edwards JR(2006)Inhibition of the proteasomal function in chondrocytes down-regulates growth plate chondrogenesis and longitudinal bone growth Endocrinology 147 3761-220
[17]  
Mundy GR(2010)Osteoblastogenesis and tumor growth in myeloma Leuk Lymphoma 51 213-504
[18]  
Harada S(2008)Pharmacologic targeting of a stem/progenitor population J Clin Invest 118 491-338
[19]  
Rodan GA(2007) is associated with enhanced bone regeneration in mice Blood 110 334-438
[20]  
Lian JB(2007)The proteasome inhibitor bortezomib affects osteoblast differentiation Br J Haematol 139 434-589